Similar articles

• [Evaluating the efficacy of interferon therapy on hepatitis C patients].

  Shiraha H, Iwasaki Y, Shiratori Y. Shiraha H, et al. Nihon Rinsho. 2004 Jul;62 Suppl 7(Pt 1):489-92. Nihon Rinsho. 2004. PMID: 15359847 Review. Japanese. No abstract available.
• [Clinical management of asymptomatic HCV carriers].

  Nakamura I, Ochiai K, Imawari M. Nakamura I, et al. Nihon Rinsho. 2004 Jul;62 Suppl 7(Pt 1):396-9. Nihon Rinsho. 2004. PMID: 15359829 Review. Japanese. No abstract available.
• Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.

  Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Kobayashi M, Arase Y, Ikeda K, Kumada H. Akuta N, et al. J Med Virol. 2006 Jan;78(1):83-90. doi: 10.1002/jmv.20507. J Med Virol. 2006. PMID: 16299715
• Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.

  Abdelmalek MF, Firpi RJ, Soldevila-Pico C, Reed AI, Hemming AW, Liu C, Crawford JM, Davis GL, Nelson DR. Abdelmalek MF, et al. Liver Transpl. 2004 Feb;10(2):199-207. doi: 10.1002/lt.20074. Liver Transpl. 2004. PMID: 14762857 Clinical Trial.
• [Hepatitis C in childhood--natural history and therapy].

  Nagata I, Murakami J, Okamoto M, Iitsuka T, Kanzaki S, Shiraki K. Nagata I, et al. Nihon Rinsho. 2004 Jul;62 Suppl 7(Pt 1):634-9. Nihon Rinsho. 2004. PMID: 15359875 Review. Japanese. No abstract available.